Results 11 to 20 of about 5,464 (192)

Abciximab in the management of acute myocardial infarction with ST-segment elevation: evidence-based treatment, current clinical use, and future perspectives [PDF]

Therapeutics and Clinical Risk Management, 2014
Artur Dziewierz,1 Tomasz Rakowski,1 Dariusz Dudek2 12nd Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland; 2Department of Interventional Cardiology, Jagiellonian University Medical College, Krakow, Poland Abstract ...
Dziewierz A, Rakowski T, Dudek D
doaj   +2 more sources

Abciximab: a reappraisal of its use in coronary care

Biologics: Targets & Therapy, 2008
Marco Valgimigli, Gianluca Campo, Matteo Tebaldi, Roberto Carletti, Chiara Arcozzi, Roberto Ferrari, Gianfranco PercocoCardiovascular Institute, Azienda Ospedaliera Universitaria S.
Marco Valgimigli, Gianluca Campo, Matteo Tebaldi, Roberto Carletti, Chiara Arcozzi, et al   +5 more
doaj   +1 more source

Comparative efficacy of eptifibatide and abciximab in primary angioplasty study

Research Reports in Clinical Cardiology, 2011
Rohan Jayasinghe1 Matias Yudi1 Sanjay Jayasinghe21Cardiology Department, Gold Coast Hospital, Griffith University, Queensland, Australia; 2Centre for Immunisation Research, Sydney, AustraliaBackground: Primary percutaneous intervention is the safest and ...
Rohan Jayasinghe, Matias Yudi, Sanjay Jayasinghe   +2 more
doaj   +3 more sources

Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention

Vascular Health and Risk Management, 2010
Jennifer Vergara-Jimenez, Pierluigi TricociDepartment of Medicine-Cardiology, Duke Clinical Research Institute, Durham, North Carolina, USAAbstract: Abciximab is a widely studied glycoprotein IIb/IIIa inhibitor, specifically in the setting of patients ...
Jennifer Vergara-Jimenez, Pierluigi Tricoci   +1 more
doaj   +1 more source

Retention of critical platelet hemostatic functions of amotosalen-UVA pathogen-reduced cryoprecipitated fibrinogen complex. [PDF]

Transfusion
Abstract Background Cryoprecipitate Anti‐Haemophilic Factor (CRYO‐AHF) is enriched for fibrinogen, VWF, FVIII, FXIII and fibronectin, but has short post‐thaw expiration due to risk of transfusion‐transmitted infection (TTI) limiting availability for rapid treatment.
Tupin F, Mouriaux C, Gatmaitan M, Kaastrup K, Yegneswaran S, Corash L, Mangin PH.   +6 more
europepmc   +2 more sources

Pathogen-reduced plasma, cryoprecipitate reduced for therapeutic plasma exchange. [PDF]

Transfusion
Abstract Background Therapeutic plasma exchange (TPE) for thrombotic thrombocytopenic purpura (TTP) and auto‐immune disorders involves repeated patient exposure to allogenic plasma with the risk of transfusion‐transmitted infection (TTI).
Tupin F, Mouriaux C, Hechler B, Kaastrup K, Yegneswaran S, Corash L, Mangin PH.   +6 more
europepmc   +2 more sources

Modeling Versus Balancing Approaches to Addressing Instrumental Variables in Weighting: A Comparison of the Outcome-Adaptive Lasso, Stable Balancing Weighting, and Stable Confounder Selection. [PDF]

Pharmacoepidemiol Drug Saf
ABSTRACT Background Variable selection is essential for propensity score (PS)‐weighted estimators. Recent work shows that including instrumental variables (IVs), associated with only treatment but not with the outcome, can impact both the bias and precision of the PS‐weighted estimators.
Choi BY, Brookhart MA.
europepmc   +2 more sources

Breaking the Barrier: Unraveling the No-Reflow Phenomenon in Cardiovascular Medicine. [PDF]

Catheter Cardiovasc Interv
ABSTRACT The no‐reflow phenomenon is a stubborn and often devastating complication in cardiovascular medicine, where blood flow is restored to an artery, yet the microvasculature remains unresponsive. First identified in 1967, this phenomenon has haunted clinicians and researchers alike, particularly in the context of acute myocardial infarction (AMI).
Howes S, Altaee O, Ramirez A, Calaquian L, Asif A, Stone C, Hammadah M, Roy D, Ramsey B, Chilton R.   +9 more
europepmc   +2 more sources

Diagnosis and Management of Hypersensitivity to Antiplatelet Drugs: EAACI Position Paper. [PDF]

Allergy
ABSTRACT Antiplatelet drug (APD) therapy is the cornerstone for the prevention of atherosclerotic cardiovascular disease. The main APDs are aspirin and thienopyridines, particularly clopidogrel. These drugs may induce hypersensitivity reactions (HSRs).
Cortellini G, Nakonechna A, Barbaud A, Bavbek S, Calogiuri G, Doña I, Kvedariene V, Laguna Martinez JJ, Liberati S, Pagani M, Romano A.   +10 more
europepmc   +2 more sources

Effects of abciximab on key pattern of human coronary restenosis in vitro: impact of the SI/MPL-ratio

BMC Cardiovascular Disorders, 2006
Background The significant reduction of angiographic restenosis rates in the ISAR-SWEET study (intracoronary stenting and antithrombotic regimen: is abciximab a superior way to eliminate elevated thrombotic risk in diabetes) raises the question of ...
Baur Regine, Müller Lutz von, Alan Mustafa, Voisard Rainer, Hombach Vinzenz   +4 more
doaj   +1 more source